Physician profile
Stephen Thurston
NPI 1417928177
$1,182.48
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $948 · 2020: $213 · 2022: $21.37.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $297.59 | 2019-2020 | |
| Emd Serono, INC. | $210.95 | 2019-2020 | |
| Allergan, INC. | $82.22 | 2019-2020 | |
| Biogen, INC. | $81.95 | 2019 | |
| Merz North America, INC. | $56.07 | 2019 | |
| Ucb, INC. | $54.77 | 2019-2020 | |
| Abbott Laboratories | $48.40 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $47.80 | 2019 | |
| Avanir Pharmaceuticals, INC. | $47.42 | 2019 | |
| Sunovion Pharmaceuticals INC. | $43.63 | 2019 | |
| Kyowa Kirin, INC. | $27.87 | 2020 | |
| Mdd US Operations, LLC | $25.22 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $24.68 | 2019 | |
| Genzyme Corporation | $22.72 | 2019 | |
| Lilly USA, LLC | $22.44 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $21.37 | 2022 | |
| Janssen Pharmaceuticals, INC | $19.99 | 2020 | |
| Alexion Pharmaceuticals, INC. | $19.15 | 2019 | |
| Harmony Biosciences LLC | $15.83 | 2020 | |
| Amneal Pharmaceuticals LLC | $12.41 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Thurston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.